Cargando…

In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. Afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Karen J, Baidoo, Kwamena E, Nayak, Tapan K, Garmestani, Kayhan, Brechbiel, Martin W, Milenic, Diane E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155408/
https://www.ncbi.nlm.nih.gov/pubmed/21845232
http://dx.doi.org/10.1186/2191-219X-1-1
_version_ 1782210119815135232
author Wong, Karen J
Baidoo, Kwamena E
Nayak, Tapan K
Garmestani, Kayhan
Brechbiel, Martin W
Milenic, Diane E
author_facet Wong, Karen J
Baidoo, Kwamena E
Nayak, Tapan K
Garmestani, Kayhan
Brechbiel, Martin W
Milenic, Diane E
author_sort Wong, Karen J
collection PubMed
description BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab')(2 )was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab')(2 )as well as planar γ-scintigraphy and PET imaging. RESULTS: The panitumumab F(ab')(2 )was successfully produced by peptic digest. The F(ab')(2 )was modified with the CHX-A"-DTPA chelate and efficiently radiolabeled with either (111)In or (86)Y. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. CONCLUSIONS: The panitumumab F(ab')(2 )fragment is a promising candidate for imaging of HER1-positive cancers.
format Online
Article
Text
id pubmed-3155408
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-31554082011-12-29 In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers Wong, Karen J Baidoo, Kwamena E Nayak, Tapan K Garmestani, Kayhan Brechbiel, Martin W Milenic, Diane E EJNMMI Res Original Research BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab')(2 )was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab')(2 )as well as planar γ-scintigraphy and PET imaging. RESULTS: The panitumumab F(ab')(2 )was successfully produced by peptic digest. The F(ab')(2 )was modified with the CHX-A"-DTPA chelate and efficiently radiolabeled with either (111)In or (86)Y. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. CONCLUSIONS: The panitumumab F(ab')(2 )fragment is a promising candidate for imaging of HER1-positive cancers. Springer 2011-06-07 /pmc/articles/PMC3155408/ /pubmed/21845232 http://dx.doi.org/10.1186/2191-219X-1-1 Text en Copyright © 2011 Wong et al; licensee Springer. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Research
Wong, Karen J
Baidoo, Kwamena E
Nayak, Tapan K
Garmestani, Kayhan
Brechbiel, Martin W
Milenic, Diane E
In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title_full In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title_fullStr In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title_full_unstemmed In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title_short In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
title_sort in vitro and in vivo pre-clinical analysis of a f(ab')(2 )fragment of panitumumab for molecular imaging and therapy of her1-positive cancers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155408/
https://www.ncbi.nlm.nih.gov/pubmed/21845232
http://dx.doi.org/10.1186/2191-219X-1-1
work_keys_str_mv AT wongkarenj invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers
AT baidookwamenae invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers
AT nayaktapank invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers
AT garmestanikayhan invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers
AT brechbielmartinw invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers
AT milenicdianee invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers